Peptide-drug conjugates (PDCs) are emerging as a precision medicine platform for targeted delivery of therapeutic payloads. By combining the targeting specificity of peptides with the potency of small molecule drugs, PDCs offer advantages over both traditional chemotherapy and antibody-drug conjugates.
The PDC approach involves conjugating a cytotoxic payload to a targeting peptide that binds to receptors overexpressed on cancer cells or diseased tissues. The peptide targets the conjugate to the site of disease, where the payload is released to exert its therapeutic effect. This targeting reduces off-target toxicity and enables higher dosing, improving the therapeutic index.
PDCs offer several advantages over antibody-drug conjugates (ADCs). Peptides are smaller than antibodies, enabling faster tumor penetration and more uniform distribution. Peptides have lower immunogenicity than antibodies, reducing the risk of immune responses. Peptides can be synthesized chemically, enabling precise control over structure and conjugation.
The Peptide-Drug Conjugates CDMO Service Market was valued at USD 345.67 million in 2025 and is projected to reach USD 480.21 million by 2032[reference:119]. This growth reflects the increasing interest in PDCs as a therapeutic modality and the need for specialized manufacturing capabilities.
Key considerations for PDC development include the choice of targeting peptide, payload, linker, and conjugation strategy. The targeting peptide must have high affinity and selectivity for the target receptor. The payload must be potent enough to provide therapeutic effect at the concentrations achieved at the target site. The linker must be stable in circulation but release the payload efficiently at the target site.
At PeptideHub, we provide custom peptide synthesis for PDC development, with capabilities for specialized modifications and conjugation. Our experienced team can support the development of PDCs from early research through to clinical manufacturing.